Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

ATG7 and ATG9A loss-of-function variants trigger autophagy impairment and ovarian failure.

Delcour C, Amazit L, Patino LC, Magnin F, Fagart J, Delemer B, Young J, Laissue P, Binart N, Beau I.

Genet Med. 2019 Apr;21(4):930-938. doi: 10.1038/s41436-018-0287-y. Epub 2018 Sep 19.

PMID:
30224786
2.

Corticosteroid receptors adopt distinct cyclical transcriptional signatures.

Le Billan F, Amazit L, Bleakley K, Xue QY, Pussard E, Lhadj C, Kolkhof P, Viengchareun S, Fagart J, Lombès M.

FASEB J. 2018 Oct;32(10):5626-5639. doi: 10.1096/fj.201800391RR. Epub 2018 May 7.

PMID:
29733691
3.

RNA-binding protein HuR enhances mineralocorticoid signaling in renal KC3AC1 cells under hypotonicity.

Lema I, Amazit L, Lamribet K, Fagart J, Blanchard A, Lombès M, Cherradi N, Viengchareun S.

Cell Mol Life Sci. 2017 Dec;74(24):4587-4597. doi: 10.1007/s00018-017-2594-x. Epub 2017 Jul 25.

PMID:
28744670
4.

HuR-Dependent Editing of a New Mineralocorticoid Receptor Splice Variant Reveals an Osmoregulatory Loop for Sodium Homeostasis.

Lema I, Amazit L, Lamribet K, Fagart J, Blanchard A, Lombès M, Cherradi N, Viengchareun S.

Sci Rep. 2017 Jul 6;7(1):4835. doi: 10.1038/s41598-017-04838-8.

5.

Nestorone® as a Novel Progestin for Nonoral Contraception: Structure-Activity Relationships and Brain Metabolism Studies.

Kumar N, Fagart J, Liere P, Mitchell SJ, Knibb AR, Petit-Topin I, Rame M, El-Etr M, Schumacher M, Lambert JJ, Rafestin-Oblin ME, Sitruk-Ware R.

Endocrinology. 2017 Jan 1;158(1):170-182. doi: 10.1210/en.2016-1426.

6.

Familial Multiplicity of Estrogen Insensitivity Associated With a Loss-of-Function ESR1 Mutation.

Bernard V, Kherra S, Francou B, Fagart J, Viengchareun S, Guéchot J, Ladjouze A, Guiochon-Mantel A, Korach KS, Binart N, Lombès M, Christin-Maitre S.

J Clin Endocrinol Metab. 2017 Jan 1;102(1):93-99. doi: 10.1210/jc.2016-2749.

7.

Identification of Multiple Gene Mutations Accounts for a new Genetic Architecture of Primary Ovarian Insufficiency.

Bouilly J, Beau I, Barraud S, Bernard V, Azibi K, Fagart J, Fèvre A, Todeschini AL, Veitia RA, Beldjord C, Delemer B, Dodé C, Young J, Binart N.

J Clin Endocrinol Metab. 2016 Dec;101(12):4541-4550. Epub 2016 Sep 7.

PMID:
27603904
8.

Three Novel Heterozygous Point Mutations of NR3C1 Causing Glucocorticoid Resistance.

Vitellius G, Fagart J, Delemer B, Amazit L, Ramos N, Bouligand J, Le Billan F, Castinetti F, Guiochon-Mantel A, Trabado S, Lombès M.

Hum Mutat. 2016 Aug;37(8):794-803. doi: 10.1002/humu.23008. Epub 2016 May 11.

PMID:
27120390
9.

Anti-Tumoral Effects of Anti-Progestins in a Patient-Derived Breast Cancer Xenograft Model.

Esber N, Cherbonnier C, Resche-Rigon M, Hamze A, Alami M, Fagart J, Loosfelt H, Lombès M, Chabbert-Buffet N.

Horm Cancer. 2016 Apr;7(2):137-47. doi: 10.1007/s12672-016-0255-4. Epub 2016 Mar 3.

PMID:
26941094
10.

Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1.

Amazit L, Le Billan F, Kolkhof P, Lamribet K, Viengchareun S, Fay MR, Khan JA, Hillisch A, Lombès M, Rafestin-Oblin ME, Fagart J.

J Biol Chem. 2015 Sep 4;290(36):21876-89. doi: 10.1074/jbc.M115.657957. Epub 2015 Jul 22.

11.

Cistrome of the aldosterone-activated mineralocorticoid receptor in human renal cells.

Le Billan F, Khan JA, Lamribet K, Viengchareun S, Bouligand J, Fagart J, Lombès M.

FASEB J. 2015 Sep;29(9):3977-89. doi: 10.1096/fj.15-274266. Epub 2015 Jun 8.

PMID:
26054365
12.

Molecular determinants of the recognition of ulipristal acetate by oxo-steroid receptors.

Petit-Topin I, Fay M, Resche-Rigon M, Ulmann A, Gainer E, Rafestin-Oblin ME, Fagart J.

J Steroid Biochem Mol Biol. 2014 Oct;144 Pt B:427-35. doi: 10.1016/j.jsbmb.2014.08.008. Epub 2014 Sep 6.

PMID:
25204619
13.

A structural explanation of the effects of dissociated glucocorticoids on glucocorticoid receptor transactivation.

Dezitter X, Fagart J, Taront S, Fay M, Masselot B, Hétuin D, Formstecher P, Rafestin-Oblin ME, Idziorek T.

Mol Pharmacol. 2014 Feb;85(2):226-36. doi: 10.1124/mol.113.085860. Epub 2013 Nov 13.

PMID:
24225022
14.

A new strategy for selective targeting of progesterone receptor with passive antagonists.

Khan JA, Tikad A, Fay M, Hamze A, Fagart J, Chabbert-Buffet N, Meduri G, Amazit L, Brion JD, Alami M, Lombès M, Loosfelt H, Rafestin-Oblin ME.

Mol Endocrinol. 2013 Jun;27(6):909-24. doi: 10.1210/me.2012-1328. Epub 2013 Apr 11.

15.

Two families with normosmic congenital hypogonadotropic hypogonadism and biallelic mutations in KISS1R (KISS1 receptor): clinical evaluation and molecular characterization of a novel mutation.

Brioude F, Bouligand J, Francou B, Fagart J, Roussel R, Viengchareun S, Combettes L, Brailly-Tabard S, Lombès M, Young J, Guiochon-Mantel A.

PLoS One. 2013;8(1):e53896. doi: 10.1371/journal.pone.0053896. Epub 2013 Jan 18.

16.

Characterization of seven novel mutations on the HEXB gene in French Sandhoff patients.

Gaignard P, Fagart J, Niemir N, Puech JP, Azouguene E, Dussau J, Caillaud C.

Gene. 2013 Jan 10;512(2):521-6. doi: 10.1016/j.gene.2012.09.124. Epub 2012 Oct 6.

PMID:
23046579
17.

Adult cases of mitochondrial DNA depletion due to TK2 defect: an expanding spectrum.

Béhin A, Jardel C, Claeys KG, Fagart J, Louha M, Romero NB, Laforêt P, Eymard B, Lombès A.

Neurology. 2012 Feb 28;78(9):644-8. doi: 10.1212/WNL.0b013e318248df2b. Epub 2012 Feb 15.

PMID:
22345218
18.

Normosmic congenital hypogonadotropic hypogonadism due to TAC3/TACR3 mutations: characterization of neuroendocrine phenotypes and novel mutations.

Francou B, Bouligand J, Voican A, Amazit L, Trabado S, Fagart J, Meduri G, Brailly-Tabard S, Chanson P, Lecomte P, Guiochon-Mantel A, Young J.

PLoS One. 2011;6(10):e25614. doi: 10.1371/journal.pone.0025614. Epub 2011 Oct 21.

19.

Structural determinants of ligand binding to the mineralocorticoid receptor.

Huyet J, Pinon GM, Fay MR, Rafestin-Oblin ME, Fagart J.

Mol Cell Endocrinol. 2012 Mar 24;350(2):187-95. doi: 10.1016/j.mce.2011.07.035. Epub 2011 Jul 25. Review.

PMID:
21820032
20.

Mineralocorticoid receptor mutations differentially affect individual gene expression profiles in pseudohypoaldosteronism type 1.

Fernandes-Rosa FL, Hubert EL, Fagart J, Tchitchek N, Gomes D, Jouanno E, Benecke A, Rafestin-Oblin ME, Jeunemaitre X, Antonini SR, Zennaro MC.

J Clin Endocrinol Metab. 2011 Mar;96(3):E519-27. doi: 10.1210/jc.2010-1486. Epub 2010 Dec 15.

PMID:
21159846
21.

Identification of periplakin as a new target for autoreactivity in idiopathic pulmonary fibrosis.

Taillé C, Grootenboer-Mignot S, Boursier C, Michel L, Debray MP, Fagart J, Barrientos L, Mailleux A, Cigna N, Tubach F, Marchal-Sommé J, Soler P, Chollet-Martin S, Crestani B.

Am J Respir Crit Care Med. 2011 Mar 15;183(6):759-66. doi: 10.1164/rccm.201001-0076OC. Epub 2010 Oct 8.

PMID:
20935114
22.

A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule.

Fagart J, Hillisch A, Huyet J, Bärfacker L, Fay M, Pleiss U, Pook E, Schäfer S, Rafestin-Oblin ME, Kolkhof P.

J Biol Chem. 2010 Sep 24;285(39):29932-40. doi: 10.1074/jbc.M110.131342. Epub 2010 Jul 22.

23.

Met909 plays a key role in the activation of the progesterone receptor and also in the high potency of 13-ethyl progestins.

Petit-Topin I, Turque N, Fagart J, Fay M, Ulmann A, Gainer E, Rafestin-Oblin ME.

Mol Pharmacol. 2009 Jun;75(6):1317-24. doi: 10.1124/mol.108.054312. Epub 2009 Mar 16.

PMID:
19289570
24.

Structural basis of spirolactone recognition by the mineralocorticoid receptor.

Huyet J, Pinon GM, Fay MR, Fagart J, Rafestin-Oblin ME.

Mol Pharmacol. 2007 Sep;72(3):563-71. Epub 2007 Jun 14.

PMID:
17569793
25.

The synthetic androgen methyltrienolone (r1881) acts as a potent antagonist of the mineralocorticoid receptor.

Takeda AN, Pinon GM, Bens M, Fagart J, Rafestin-Oblin ME, Vandewalle A.

Mol Pharmacol. 2007 Feb;71(2):473-82. Epub 2006 Nov 14.

PMID:
17105867
26.

Mineralocorticoid receptor mutations are the principal cause of renal type 1 pseudohypoaldosteronism.

Pujo L, Fagart J, Gary F, Papadimitriou DT, Claës A, Jeunemaître X, Zennaro MC.

Hum Mutat. 2007 Jan;28(1):33-40.

PMID:
16972228
27.

Crystal structure of a mutant mineralocorticoid receptor responsible for hypertension.

Fagart J, Huyet J, Pinon GM, Rochel M, Mayer C, Rafestin-Oblin ME.

Nat Struct Mol Biol. 2005 Jun;12(6):554-5. Epub 2005 May 22.

PMID:
15908963
28.

The Met852 residue is a key organizer of the ligand-binding cavity of the human mineralocorticoid receptor.

Fagart J, Seguin C, Pinon GM, Rafestin-Oblin ME.

Mol Pharmacol. 2005 May;67(5):1714-22. Epub 2005 Feb 16.

PMID:
15716462
29.

11-deoxycorticosterone is a potent agonist of the rainbow trout (Oncorhynchus mykiss) mineralocorticoid receptor.

Sturm A, Bury N, Dengreville L, Fagart J, Flouriot G, Rafestin-Oblin ME, Prunet P.

Endocrinology. 2005 Jan;146(1):47-55. Epub 2004 Oct 14.

PMID:
15486226
31.

[Agonists and antagonists of mineralocorticoids. The relation between structure and activity].

Fagart J, Pinon GM, Rafestin-Oblin ME.

Ann Cardiol Angeiol (Paris). 2004 Jun;53(3):154-7. Review. French.

PMID:
15291173
32.
33.

Identification of steroid ligands able to inactivate the mineralocorticoid receptor harboring the S810L mutation responsible for a severe form of hypertension.

Pinon GM, Fagart J, Souque A, Auzou G, Vandewalle A, Rafestin-Oblin ME.

Mol Cell Endocrinol. 2004 Mar 31;217(1-2):181-8.

PMID:
15134816
34.

Glucocorticoid metabolism by 11-beta hydroxysteroid dehydrogenase type 2 modulates human mineralocorticoid receptor transactivation activity.

Bocchi B, Fagart J, Cluzeaud F, Fay M, Rafestin-Oblin ME, Farman N.

J Steroid Biochem Mol Biol. 2003 Feb;84(2-3):239-44.

PMID:
12711009
35.

The severe form of hypertension caused by the activating S810L mutation in the mineralocorticoid receptor is cortisone related.

Rafestin-Oblin ME, Souque A, Bocchi B, Pinon G, Fagart J, Vandewalle A.

Endocrinology. 2003 Feb;144(2):528-33.

PMID:
12538613
36.

11beta-hydroxyprogesterone acts as a mineralocorticoid agonist in stimulating Na+ absorption in mammalian principal cortical collecting duct cells.

Rafestin-Oblin ME, Fagart J, Souque A, Seguin C, Bens M, Vandewalle A.

Mol Pharmacol. 2002 Dec;62(6):1306-13.

PMID:
12435797
37.

A single amino acid mutation of ala-773 in the mineralocorticoid receptor confers agonist properties to 11beta-substituted spirolactones.

Auzou G, Fagart J, Souque A, Hellal-Lévy C, Wurtz JM, Moras D, Rafestin-Oblin ME.

Mol Pharmacol. 2000 Oct;58(4):684-91.

PMID:
10999937
38.

Crucial role of the H11-H12 loop in stabilizing the active conformation of the human mineralocorticoid receptor.

Hellal-Levy C, Fagart J, Souque A, Wurtz JM, Moras D, Rafestin-Oblin ME.

Mol Endocrinol. 2000 Aug;14(8):1210-21.

PMID:
10935545
39.

A new model for 20-hydroxyecdysone and dibenzoylhydrazine binding: a homology modeling and docking approach.

Wurtz JM, Guillot B, Fagart J, Moras D, Tietjen K, Schindler M.

Protein Sci. 2000 Jun;9(6):1073-84.

40.

Mechanistic aspects of mineralocorticoid receptor activation.

Hellal-Levy C, Fagart J, Souque A, Rafestin-Oblin ME.

Kidney Int. 2000 Apr;57(4):1250-5. Review.

41.

[Corticosteroid hormones: mechanisms involved in the recognition of aldosterone by mineralocorticoid receptors].

Hellal-Levy C, Fagart J, Souque A, Rafestin-Oblin ME.

J Soc Biol. 1999;193(4-5):355-60. Review. French.

PMID:
10689617
42.

Specific hydroxylations determine selective corticosteroid recognition by human glucocorticoid and mineralocorticoid receptors.

Hellal-Levy C, Couette B, Fagart J, Souque A, Gomez-Sanchez C, Rafestin-Oblin M.

FEBS Lett. 1999 Dec 24;464(1-2):9-13.

43.

Properties of polyglutamine expansion in vitro and in a cellular model for Huntington's disease.

Lunkes A, Trottier Y, Fagart J, Schultz P, Zeder-Lutz G, Moras D, Mandel JL.

Philos Trans R Soc Lond B Biol Sci. 1999 Jun 29;354(1386):1013-9. Review.

44.

Photoaffinity labelling of the human mineralocorticoid receptor with steroids having a reactive group at position 3, 18 or 21.

Fagart J, Couette B, Souque A, Davioud E, Marquet A, Rafestin-Oblin ME.

Biochim Biophys Acta. 1998 Oct 14;1388(1):35-44.

PMID:
9774704
45.

Antagonism in the human mineralocorticoid receptor.

Fagart J, Wurtz JM, Souque A, Hellal-Levy C, Moras D, Rafestin-Oblin ME.

EMBO J. 1998 Jun 15;17(12):3317-25.

46.

Folding requirements of the ligand-binding domain of the human mineralocorticoid receptor.

Couette B, Jalaguier S, Hellal-Levy C, Lupo B, Fagart J, Auzou G, Rafestin-Oblin ME.

Mol Endocrinol. 1998 Jun;12(6):855-63.

PMID:
9626661
47.

New steroidal diazo ketones as potential photoaffinity labeling reagents for the mineralocorticoid receptor: synthesis and biological activities.

Davioud E, Fagart J, Souque A, Rafestin-Oblin ME, Marquet A.

J Med Chem. 1996 Jul 5;39(14):2860-4.

PMID:
8709117
48.

Ligand-induced conformational change in the human mineralocorticoid receptor occurs within its hetero-oligomeric structure.

Couette B, Fagart J, Jalaguier S, Lombes M, Souque A, Rafestin-Oblin ME.

Biochem J. 1996 Apr 15;315 ( Pt 2):421-7.

49.

Sulfhydryl groups are involved in the binding of agonists and antagonists to the human mineralocorticoid receptor.

Souque A, Fagart J, Couette B, Rafestin-Oblin ME.

J Steroid Biochem Mol Biol. 1996 Mar;57(5-6):315-21.

PMID:
8639467
50.

The mineralocorticoid activity of progesterone derivatives depends on the nature of the C18 substituent.

Souque A, Fagart J, Couette B, Davioud E, Sobrio F, Marquet A, Rafestin-Oblin ME.

Endocrinology. 1995 Dec;136(12):5651-8.

PMID:
7588320

Supplemental Content

Loading ...
Support Center